| Description |
Epobis, a dendrimeric peptide, is a recombinant form of erythropoietin. Epobis is a potent erythropoietin receptor agonist. Epobis promotes neuritogenesis in primary motoneurons. Epobis decrease TNF release and crosses the blood-brain barrier. Epobis has anti-inflammatory and memory enhancing properties[1].
|
| Related Catalog |
|
| In Vitro |
Epobis (0-8.82 μM) stimulates neurite outgrowth from motor neurons in a dose-dependent manner with maximal stimulation at 0.33 μM[1]. Epobis (0-8.82 μM; 24 h) reduces release of TNF and improves the survival of the L929 cells[1]. Cell Viability Assay[1] Cell Line: L929 cells Concentration: 0-8.82 μM Incubation Time: 24 hours Result: Had a significantly higher viability of 64% in a concentration of 8.4 μM, whereas the highest viability (68%) in a concentration of 2.7 μM.
|
| In Vivo |
Epobis (10 mg/kg; i.h.; Wistar rats) can cross the blood-brain barrier (BBB)[1]. Epobis (10 mg/kg; i.h.) has an anti-inflammatory effect in mice of multiple sclerosis model[1]. Epobis (10 mg/kg; i.h.; old (>18 month) rats and in rats experiencing early stage AD) improves social memory[1]. Animal Model: Wistar rats (200 g)[1] Dosage: 10 mg/kg Administration: Subcutaneous injection; once Result: Had detectable already 15 min after administration and remained detectable in the blood for at least 24 h. Animal Model: Wistar rats with multiple sclerosis model (200 g)[1] Dosage: 10 mg/kg Administration: Subcutaneous injection; once Result: Had no significant effects on the weight changes or the survival of experimental autoimmune encephalomyelitis (EAE) animals. Animal Model: Old (>18 month) rats and in rats experiencing early stage AD[1] Dosage: 10 mg/kg Administration: Subcutaneous injection; once Result: Had significantly lower than that of vehicle-treated animals.
|
